Floatz Rating
BB66/100
Confidence
Indicative
Sponsor
Masonic Cancer Center, University of Minnesota
Modality
protein_peptide
Development Phase
Phase 3
Status
Dormant
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
63High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT00623077CT.gov MT2004-30: Tomotherapy for Solid Tumors | — | Terminated | — | — | — |
NCT00069940CT.gov Vaccine Therapy and Sargramostim in Treating Patients With Sarcoma or Brain Tumor | — | Completed | — | — | — |
NCT00004157CT.gov Interleukin-11 Plus Filgrastim Prior to Peripheral Stem Cell Transplantation in Patients With Non-Hodgkin's Lymphoma, Hodgkin's Disease, Breast Cancer, or Other Solid Tumors | — | Completed | — | — | — |
NCT00004250CT.gov Isolated Limb Infusion of Chemotherapy in Treating Patients With Melanoma or Soft Tissue Sarcoma of the Arm or Leg That Cannot Be Removed By Surgery | — | Completed | — | — | — |
NCT00003926CT.gov Amifostine to Protect From Side Effects of PSCT in Treating Patients With Solid Tumors | — | Terminated | — | — | — |
NCT00003657CT.gov High-dose ICE With Amifostine | — | Completed | — | — | — |
NCT00003408CT.gov Biological Therapy Following Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Cancer | — | Completed | — | — | — |
NCT00003141CT.gov Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Infants With Malignant Brain or Spinal Cord Tumors | — | Completed | — | — | — |
NCT00003425CT.gov Phase I/II Study of Escalating-Dose Melphalan w/Autologous SCS & Amifostine Cytoprotect | — | Completed | — | — | — |
NCT00002641CT.gov Surgery With or Without Chemotherapy in Treating Patients With Soft Tissue Sarcoma | — | Completed | — | — | — |
Show 1 more trialShow fewer
NCT00002515CT.gov Combination Chemotherapy Followed by Bone Marrow Transplantation in Treating Patients With Rare Cancer | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
73High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Sarcoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Nivestim (this asset) | Masonic Cancer Center, University of Minnesota | P3 | BB · 66 |
| Etoposide | National Cancer Institute (NCI) | P2 | BB |
| Cyclophosphamide | Essen Biotech | P2 | BB |
| Isocyclophosphamide | City of Hope Medical Center | P3 | BB |
| Adriamycin | City of Hope Medical Center | P3 | BB |
| Carboplatin | OHSU Knight Cancer Institute | P2 | BB |
| Cis-Diamminedichloroplatinum Ii | Roswell Park Cancer Institute | P2 | BB |
| Sodium Thiosulfate | Mayo Clinic | P3 | BB |
| Vincristine Sulfate | Societe Internationale d'Oncologie Pediatrique | P2 | BB |
+42 more in the Sarcoma cohort
Other indications for Nivestim
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Burkitt Lymphoma | — | P4 | BBB · 78 |
| Neutropenia | — | P4 | BBB · 76 |
| Mycosis Fungoides | — | P4 | BBB · 75 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Nivestim in Sarcoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/n-met-g-csf-sarcoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →